NCT01564316

Brief Summary

Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2005

Completed
6.9 years until next milestone

First Submitted

Initial submission to the registry

March 11, 2012

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 27, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
Last Updated

April 15, 2016

Status Verified

March 1, 2016

Enrollment Period

8.7 years

First QC Date

March 11, 2012

Last Update Submit

April 14, 2016

Conditions

Biomarker With Neurodegeneration Patients

Study Arms (1)

neurodegeneration patients

•neurodegeneration patients and control group include dementia patients visited the part of neurology

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

neurodegeneration patients group include dementia patients visited the part of neurology. (almost after diagnosis)

You may qualify if:

  • neurodegeneration patients and control group include dementia patients visited the part of neurology.
  • over the age of 18
  • when participants can understand subject of this study
  • Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.

You may not qualify if:

  • under eighteen years of age
  • when participants cannot understand subject of this study
  • cannot accept this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurology, Seoul National University Hospital

Seoul, Seoul, 110744, South Korea

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum:10ml WHO: neurodegeneration patients and control group include dementia patients visited the part of neurology.

Study Officials

  • Manho Kim, Professor

    Seoul National University Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2012

First Posted

March 27, 2012

Study Start

May 1, 2005

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

April 15, 2016

Record last verified: 2016-03

Locations

KR(1)